Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of “Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $33.20.

Several research analysts have commented on CPRX shares. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th.

Insider Buying and Selling

In related news, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares in the company, valued at $54,870. The trade was a 91.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total value of $256,233.39. Following the sale, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. This trade represents a 73.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently made changes to their positions in CPRX. Oregon Public Employees Retirement Fund lifted its holdings in shares of Catalyst Pharmaceuticals by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 472 shares during the period. Jones Financial Companies Lllp raised its position in Catalyst Pharmaceuticals by 14.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 498 shares during the last quarter. Mission Wealth Management LP lifted its stake in Catalyst Pharmaceuticals by 5.0% during the 2nd quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 510 shares during the period. New York State Teachers Retirement System lifted its stake in Catalyst Pharmaceuticals by 0.4% during the 2nd quarter. New York State Teachers Retirement System now owns 149,887 shares of the biopharmaceutical company’s stock valued at $3,253,000 after acquiring an additional 577 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of Catalyst Pharmaceuticals by 2.0% in the 2nd quarter. Amalgamated Bank now owns 32,619 shares of the biopharmaceutical company’s stock valued at $708,000 after acquiring an additional 654 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $24.45 on Thursday. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 14.22, a price-to-earnings-growth ratio of 0.82 and a beta of 0.74. The stock has a 50 day moving average price of $23.62 and a 200-day moving average price of $21.90. Catalyst Pharmaceuticals has a one year low of $19.05 and a one year high of $26.58.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).